The waning of the COVID-19 pandemic is reshaping the healthcare industry once again. Vaccine makers and pharmacy chains are seeing a decline in the number of people getting COVID shots, while makers of at-home rapid tests are going out of business. Companies that produced personal protective equipment have also shut down. The shift in demand is evident as Pfizer cuts $9 billion from its annual sales forecast due to declining demand for its COVID shots. While some healthcare businesses are benefiting from the return of routine checkups and procedures, others are feeling the pressure to adjust their expectations.
Despite an affirmative FDA advisory committee vote, the agency declined to approve Alnylam Pharmaceuticals’ Onpattro for treating the heart complications caused by a rare, inherited protein disorder. But Alnylam has other drugs candidates for the disease, including one expected to post Phase 3 data in the first half of 2024.
Alnylam gives up on expanded use of heart-disease drug in US after FDA declines approval reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
(Reuters) -Alnylam Pharmaceuticals said on Monday it would not pursue expanded use of its drug to treat a potentially fatal heart disease in the U.S. after the Food and Drug Administration declined to approve the medication despite a favorable recommendation from its advisers. The regulator, in its so-called complete response letter, said the drug patisiran did not meaningfully improve the condition of patients with heart muscle issues or cardiomyopathy caused by ATTR amyloidosis, characterized
Ionis Stock Climbs On Late-Stage Trial Results For Body Fat Disorder investors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investors.com Daily Mail and Mail on Sunday newspapers.